NCT04654481 is a NA clinical trial of HCFWO in Chronic Obstructive Pulmonary Disease, sponsored by Icahn School of Medicine at Mount Sinai.

Who is sponsoring NCT04654481?

NCT04654481 is sponsored by Icahn School of Medicine at Mount Sinai.

What drugs are being tested in NCT04654481?

Interventions in NCT04654481: HCFWO, Standard Care Plus Monitoring.

What condition does NCT04654481 study?

NCT04654481 studies Chronic Obstructive Pulmonary Disease, Chronic Cough, Covid19.

Is NCT04654481 still recruiting?

NCT04654481 is currently terminated. Last updated 5 May 2022.

Last reviewed 2022-05-05 · How we verify

NCT04654481

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of AffloVest in At-Risk Respiratory Patients During COVID-19 Pandemic

Terminated NA Last updated 5 May 2022

What this trial tests

NA trial testing HCFWO in Chronic Obstructive Pulmonary Disease in 1 participant. Terminated before completion.

Timeline

20 July 2021

Primary endpoint
19 October 2021

19 October 2021

Quick facts

Lead sponsor	Icahn School of Medicine at Mount Sinai
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	supportive care
Enrollment	1
Start date	20 July 2021
Primary completion	19 October 2021
Estimated completion	19 October 2021
Sites	1 location across United States

Drugs / interventions tested

HCFWO
Standard Care Plus Monitoring

Conditions studied

Chronic Obstructive Pulmonary Disease — all drugs for Chronic Obstructive Pulmonary Disease →
Chronic Cough — all drugs for Chronic Cough →
Covid19 — all drugs for Covid19 →

Sponsor

Icahn School of Medicine at Mount Sinai

Who can join

18 and older, any sex, with Chronic Obstructive Pulmonary Disease or Chronic Cough. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to investigate the addition of high frequency chest wall oscillation (HFCWO) therapy to the prescribed care regimen to support the diaphragm during airway clearance among post-COVID patients with COPD and chronic productive cough as a way to limit the advancement of pulmonary symptoms and need for critical services during recovery from COVID-19.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

At a crossroads: coronavirus disease 2019 recovery and the risk of pulmonary vascular disease.
Cascino TM, Desai AA, Kanthi Y. · · 2021 · cited 10× · PMID 34127622 · DOI 10.1097/mcp.0000000000000792

Verify or expand the search:

Other recruiting trials for Chronic Obstructive Pulmonary Disease

Currently open trials in the same condition.

NCT06749262 — Inclined Versus Standard Exercise for COPD Patients · NA · recruiting
NCT07406659 — Different Inspiratory Muscle Trainings in Patients With COPD · NA · recruiting
NCT07051707 — Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD · NA · recruiting
NCT07418736 — A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease · Phase 2 · recruiting
NCT07069829 — Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo · recruiting

Other Icahn School of Medicine at Mount Sinai trials

Trials by the same sponsor.

NCT07094308 — The LIFT-ECHO Last Mile Project · NA · not yet recruiting
NCT07291427 — Chronic Subdural Hematoma Embolization With Detachable Coils · not yet recruiting
NCT07194187 — High Intensity Focused Ultrasound (HIFU) Ablation for Treatment of Prostate Tissue in Bladder Outlet Obstruction · NA · not yet recruiting
NCT07260916 — Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation · NA · not yet recruiting
NCT07487948 — Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04654481 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Icahn School of Medicine at Mount Sinai
Last refreshed: 5 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04654481.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing